INDIGO Biosciences, leader in Nuclear Receptor Research, provides the world’s largest portfolio of Nuclear Receptor Assay kits using luciferase reporter technology.
Those kits are all-inclusive, cell-based, robust, and ready to use for either screening small numbers of test compounds or HTS application.
With a fast-growing business in the USA, INDIGO Biosciences wishes to benefit from increased European exposure to capture new market shares.
Bertin Pharma is one of the major European players for the supply of reagents and assay kits dedicated to the research and development for the pharmaceutical, cosmetic and food industries.
Bertin Pharma has marketed biological reagent ranges for over 25 years. Its long R&D experience combined with its International distributor channels enable to deliver life science tools on time and to support customers throughout their experimentation.
Bertin Pharma completes, with this new range of Nuclear Receptor Assay kits, its existing ranges of biomarker assays applied to his expertise areas that are metabolic syndrome, hypertension or even oncology.
“It has been a real honor to be introduced to Fred and his company and we rapidly found a lot of complementarity in our business. The Nuclear Assay range perfectly fit with our customer’s needs, and will empower our commercial activity.” Said Patrick Vitaux, Bioreagent Dpt Manager – Bertin Pharma
“We are pleased to have reached an agreement with Bertin Pharma to expand our distribution network in Europe. We look forward to working with Patrick and his team to bring INDIGO’s assay portfolio to their customers throughout the region.” Fred Marroni, CEO – INDIGO Biosciences.